Search

Displaying results 2541 - 2550 of 7897 in total
  1. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    It has a weak inhibitory effect on GABA receptor binding sites. … Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).

  2. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential … for abuse in addition to a low risk of dependence [L5074].

  3. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). … [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in

  4. Drug

    Phenolphthalein

    go.drugbank.com/drugs/DB04824
    ApprovedWithdrawn

    Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.

    International brands: Feen-a-mint gum, Feen-a-mint laxative mintsMixtures: Lax-BO Tab, Bilex Tab
  5. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L47153,L47158] Somatrogon is available as a once-weekly subcutaneous injection.[L39080,L47153] … Somatrogon is a long-acting recombinant human growth hormone.

  6. Drug

    Teclozan

    go.drugbank.com/drugs/DB13205
    Investigational

    Teclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.

  7. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    [A241185, A241175] Olokizumab is a humanized anti-IL-6 IgG4κ antibody that directly blocks gp130 binding at IL-6 Site 3.[A241045] … Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.

  8. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.

  9. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. … APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation.

  10. Drug

    Dimethyl fumarate

    go.drugbank.com/drugs/DB08908
    ApprovedInvestigational

    Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.